This discussion examines the key considerations oncologists weigh when choosing between chemotherapy alone or chemotherapy ...

Tarlatamab combined with PD-L1 inhibitors shows potential in improving survival for ES-SCLC, with a median OS of 25.3 months. The combination may bypass tumor immune evasion by redirecting T-cells to ...

3D rendering of a checkpoint inhibitor binding PD-1, a protein on the surface of an immune T cell. This article is part of an ongoing series on checkpoint inhibitors, a novel cancer immunotherapy.

This discussion provides a clear overview of current treatment standards and ongoing challenges in the management of advanced ...

Comparative real-world survival of first-line atezolizumab, nivolumab, and pembrolizumab in older patients with metastatic non–small cell lung cancer. This is an ASCO Meeting Abstract from the 2025 ...

Merck’s MRK shares have risen 9.6% in a month. The company’s stock declined after it announced third-quarter results. Though it beat estimates for both earnings and sales, its blockbuster PD-L1 ...

"PD-1 and PD-L1 Inhibitors Clinical Landscape"DelveInsight's,“PD-1 and PD-L1 Inhibitors - Competitive landscape, 2025,” report provides comprehensive insights about 180+ companies and 200+ drugs in PD ...

Programmed cell death ligand 1 (PD-L1) inhibitors versus programmed cell death 1 (PD-1) inhibitors for the first-line therapy of extensive-stage small cell lung cancer: A propensity score-matched ...

Signals for keratoacanthoma and cutaneous squamous cell carcinoma (cSCC) with programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors were detected in an analysis of ...

Company to deliver oral and poster presentations for data on leronlimab’s action on PD-L1 expression and patient survival in triple-negative breast cancer VANCOUVER, Washington, Sept. 25, 2025 (GLOBE ...

Merck MRK has made substantial investments in strategic mergers and acquisitions (M&A) deals over the past few years to build ...

Biomarker testing for 11 oncogenes at diagnosis enables personalized lung cancer treatment, moving away from a ...